Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases